Overview

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Status:
Not yet recruiting

Trial end date:
2023-06-23

Target enrollment:

Participant gender:

Summary

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation. Acute exacerbation, especially frequent exacerbation, is associated with an increased risk of death in COPD patients. The most common causes of acute attacks are viral and bacterial infections. This study will assess the efficacy and safety of sitafloxacin, a quinolone antibacterial drug, in participants with AECOPD.

Phase:

Phase 4

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Treatments:

Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Sitafloxacin